Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Repka

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Current Opinion in Oncology|April 29, 1998
Peripheral blood versus bone marrow for hematopoietic cell transplantationT Repka, D Weisdorf
Progress in Clinical and Biological Research|January 1, 1989
Reticulocytosis: defective reticulin degradation, a case reportT Repka, B H Rank
Blood|November 15, 1991
Hydroxyl radical formation by sickle erythrocyte membranes: role of pathologic iron deposits and cytoplasmic reducing agentsT Repka, R P Hebbel
Transfusion|August 5, 2000
Nonmyeloablative HPC transplantationT Repka, D J Weisdorf
The Journal of Clinical Investigation|December 1, 1992
Detection, characterization, and bioavailability of membrane-associated iron in the intact sickle red cellT Sugihara, T Repka, R P Hebbel
Experimental Hematology|October 12, 1999
Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neuS Cooley, L J Burns, T Repka, et al.
Blood|September 1, 1995
Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivoO Shalev, T Repka, A Goldfarb, et al.
Blood|November 15, 1993
Nonrandom association of free iron with membranes of sickle and beta-thalassemic erythrocytesT Repka, O Shalev, R Reddy, et al.
The Journal of Clinical Investigation|April 1, 1993
Effect of excess alpha-hemoglobin chains on cellular and membrane oxidation in model beta-thalassemic erythrocytesM D Scott, J J van den Berg, T Repka, et al.
Bone Marrow Transplantation|January 16, 2007
Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trialM Markova, J N Barker, J S Miller, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Current Opinion in Oncology|April 29, 1998
Peripheral blood versus bone marrow for hematopoietic cell transplantationT Repka, D Weisdorf
Progress in Clinical and Biological Research|January 1, 1989
Reticulocytosis: defective reticulin degradation, a case reportT Repka, B H Rank
Blood|November 15, 1991
Hydroxyl radical formation by sickle erythrocyte membranes: role of pathologic iron deposits and cytoplasmic reducing agentsT Repka, R P Hebbel
Transfusion|August 5, 2000
Nonmyeloablative HPC transplantationT Repka, D J Weisdorf
The Journal of Clinical Investigation|December 1, 1992
Detection, characterization, and bioavailability of membrane-associated iron in the intact sickle red cellT Sugihara, T Repka, R P Hebbel
Experimental Hematology|October 12, 1999
Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neuS Cooley, L J Burns, T Repka, et al.
Blood|September 1, 1995
Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivoO Shalev, T Repka, A Goldfarb, et al.
Blood|November 15, 1993
Nonrandom association of free iron with membranes of sickle and beta-thalassemic erythrocytesT Repka, O Shalev, R Reddy, et al.
The Journal of Clinical Investigation|April 1, 1993
Effect of excess alpha-hemoglobin chains on cellular and membrane oxidation in model beta-thalassemic erythrocytesM D Scott, J J van den Berg, T Repka, et al.
Bone Marrow Transplantation|January 16, 2007
Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trialM Markova, J N Barker, J S Miller, et al.
Pageof 1